The 37th Annual Meeting of the Japanese Society for the Study of Xenobiotics in Yokohama

Program

Timetable

Timetable

General Session

• Oral Presentation
• Poster Presentation (Final for Best Poster Award)
• Poster Presentation

Special Lecture (co-sponsored by Annual meeting and Short course)

November 7 (Mon.) 18:00-19:00 1F Main Hall

• ChairFumiyoshi Yamashita
  Graduate School of Pharmaceutical Sciences, Kyoto University

Contribution of Mass Spectrometry to Phamacokinetics

• SpeakerKoichi Tanaka
  Shimadzu Corporation Mass Spectrometry Research Laboratory

Special Lecture

November 8 (Tue.) 9:00-10:00 1F Main Hall

• ChairHideki Hirabayashi
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

From Invention, to Innovation

• SpeakerTakanori Takebe
  Institute of Research, Tokyo Medical and Dental University /
  Center for Stem Cell and Organoid Medicine,
  Cincinnati Children's Hospital Medical Center

Keynote Lecture 1

November 8 (Tue.) 13:30-14:30 1F Main Hall

• ChairShinji Iwasaki
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

Towards Whole-body/organ Imaging with Single-cell Resolution

• SpeakerHiroki R. Ueda
  Department of Systems Pharmacology, Graduate School of Medicine, The University of Tokyo

Keynote Lecture 2

November 8 (Tue.) 14:30-15:30 1F Main Hall

• ChairToshiya Moriwaki
  Pharmaceutical Development Division, Towa Pharmacetical CO.,LTD

Muse cell treatment: Next-generation medical revolution compatible with the 'body's natural repair systems'

• SpeakerMari Dezawa
  Department of Stem Cell Biology and Histology,
  Tohoku University Graduate School of Medicine

Keynote Lecture 3

November 8 (Tue.) 15:30-16:00 1F Main Hall

• ChairHiroshi Mizuuchi
  DMPK Research Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation

Astellas' Frontiers of Intelligence Drug Discovery

• SpeakerKenji Tabata
  Discovery Intelligence, Appried Research & Operations,
  Astellas Pharma Inc.

JSSX President's Session

November 9 (Wed.) 16:15-17:30 Room A (3F 315)
*Satellite Room : Room B (3F 313+314), Room C (3F 311+312)

• ChairFumiyoshi Yamashita
  Graduate School of Pharmaceutical Sciences, Kyoto University

Toward the Future of Pharmaceuticals in Society 5.0

• SpeakerYuji Ikegaya
  Graduate School of Pharmaceutical Sciences,
  The University of Tokyo

<Panel discussion>

• FacilitatorHideki Hirabayashi
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
• PanelistYuji Ikegaya
  Graduate School of Pharmaceutical Sciences, The University of Tokyo
• PanelistFumiyoshi Yamashita
  Graduate School of Pharmaceutical Sciences, Kyoto University
• PanelistHiroshi Mizuuchi
  DMPK Research Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation
• PanelistShingo Sakamoto
  Shionogi & Co., Ltd.

Special Symposium 1

November 8 (Tue.) 10:00-12:00 1F Main Hall

The interface between Nobel Prize-winning technologies and pharmacokinetic research

• ChairsSyunsuke Yamamoto
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
•  Hiroyuki Mizuguchi
  Graduate School of Pharmaceutical Sciences, Osaka University

• CS1-1Development of functional enterocytes and hepatocytes by using regenerative medicine-derived techniques for pharmaceutical research
• SpeakerHiroyuki Mizuguchi
  Graduate School of Pharmaceutical Sciences, Osaka University
• CS1-2Development of delivery technology for genome editing therapy for muscular dystrophy
• SpeakerAkitsu Hotta
  CiRA, Kyoto University
• CS1-3The principle and applications of STED microscopy
• SpeakerHiroshi Kawabe
  Department of Pharmacology, Gunma University Graduate School of Medicine
• CS1-4Structural dynamics and drug interactions of P-glycoprotein
• SpeakerTakeshi Murata
  Graduate School of Science, Chiba University

Special Symposium 2

November 9 (Wed.) 13:00-15:30 Room C (3F 311+312)

What are Exosomes?
-Extracellular Vesicles: from bench to clinical application-

• ChairsMasaaki Kakehi
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
•  Kentaro Otake
  Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited

• CS2-1Exosome engineering for biomedical applications
• SpeakerKazunari Akiyoshi
  Graduate School of Engineering, Kyoto University
• CS2-2Analysis of pharmacokinetics of exosomes and therapeutic application of exosomes
• SpeakerYuki Takahashi
  Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University
• CS2-3Development of cancer diagnostic and therapeutic methods by targeting exosomes
• SpeakerYusuke Yoshioka
  Department of Molecular and Cellular Medicine, Institute of Medical Science, Tokyo Medical University
• CS2-4Utilization of extracellular vesicles in neuroscience drug discovery
• SpeakerKentaro Otake
  Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited

Special Symposium 3

November 10 (Thu.) 9:00-11:30 Room D (4F 411+412)

IQ Consortium Symposium
-Advance Drug Research and Clinical Development to Patients-

• ChairsAkihiro Hisaka
  Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University
•  Yuu Moriya
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

• CS3-1Evaluation of PBPK Models for Organ-Impaired Populations
• SpeakerSheila Annie Peters
  Boehringer Ingelheim Pharma GmbH & Co.
• CS3-2Use of PBPK modeling for predicting drug-food interactions -an industry perspective」
• SpeakersArian Emami Riedmaier
  Certara
•  Kesisoglou, Filippos
  MSD
• CS3-3Current practices, gap analysis, and proposed workflows for PBPK modeling of cytochrome P450 induction: An industry perspective
• SpeakerMasakatsu Kotsuma
  Quantitative Clinical Pharmacology, Daiichi Sankyo Co., Ltd.
• CS3-4In Vitro to In Vivo Correlations of Transporter Based Drug-Drug Interactions: Learnings from IQ Transporter Working Group Data Collection Project
• SpeakerKimio Tohyama
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

Special Symposium 4

November 10 (Thu.) 13:00-15:30 Room A (3F 315)

The in vitro BBB model in Japan
-State-of-the art technology & Future perspective-

• ChairsHiroyuki Kusuhara
  Graduate School of Pharmaceutical Sciences, the University of Tokyo
•  Shinji Iwasaki
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

• CS4-1Development of advanced human blood-brain barrier models that facilitate characterization of brain penetration properties of CNS drugs
• SpeakerTomomi Furihata
  Laboratory of Clinical Pharmacy & Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
• CS4-2A breakthrough in drug discovery by new technology of in vitro human BBB models
• SpeakerYukio Takeshita
  Blood-Brain Barrier Research Center, Yamaguchi University Graduate School of Medicine/ Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate school of Medicine
• CS4-3Development of human iPS cell derived-brain microvascular endothelial cells in the BBB model for application in drug development
• SpeakerTadahiro Hashita
  Graduate School of Pharmaceutical Sciences, Nagoya City University
• CS4-4In vitro BBB model and drug development
• SpeakerKenji Kawabata
  Laboratory of Cell Model for Drug Discovery, National Institutes of Biomedical Innovation, Health, and Nutrition
• CS4-5Blood-Brain Barrier In Vitro Models with Open Networks for Screening of Receptor-Mediated Transport
• SpeakerMichiya Matsusaki
  Graduate School of Engineering, Osaka University

Special Symposium 5

November 10 (Thu.) 13:00-15:30 Room B (3F 313+314)

Future perspective of "Tissue clearing technology" for evaluation of biodistribution.

• ChairsSyunsuke Yamamoto
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
•  Sohei Nakayama
  MiltenyiBiotec K.K.

• CS5-1Cell-type-specific transduction in mouse CNS using blood-brain-barrier-penetrating AAV vector
• SpeakerAyumu Konno
  Department of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine
• CS5-2Investigation of neural circuits controlling hibernation using whole-mount imaging of optically cleared brain
• SpeakerHiroshi Yamaguchi
  Research Institute of Environmental Medicine, Nagoya University
• CS5-3Development of Advanced Imaging and Diagnostic Techniques Based on Quantum Nano-Optics for Pharmacokinetics
• SpeakerHiroshi Yukawa
  Institute for Quantum Life Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology / Institute of Nano-Life-Sciences, Institutes of Innovation for Future Society, Nagoya University
• CS5-4Cutting-edge methodology for biodistribution evaluation opened up by recent advances in tissue clearing and light-sheet microscopy
• SpeakerSyunsuke Yamamoto
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

Toxicology Session

November 10 (Thu.) 13:00-15:30 Room F (4F 418)

Interface between toxicology and DMPK

• ChairsTadahiro Shinozawa
  Research, Takeda Pharmaceutical Company Limited
•  Kosei Ito
  Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University

• TS-1Consideration of Species differences in Drug-metabolism on Genotoxicity Assessment
• SpeakerNaoki Koyama
  Global Drug Safety, Eisai Co., Ltd.
• TS-2Drug-induced convulsion liability assessment using in vitro primary rat cortical neurons – comparison with in vivo convulsion model –
• SpeakerYuki Seki
  Global Drug Safety, Eisai Co., Ltd.
• TS-3Proposals for predicting drug efficacy/safety based on the estimation of intracellular concentrations; from the perspective of in vitro experiments- and modeling-based pharmacokinetic analyses
• SpeakerTakashi Yoshikado
  Yokohama University of Pharmacy
• TS-4Where does modeling lead pharmacology and pharmacotherapy?
• SpeakerAkihiro Hisaka
  Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University

Symposium 1 (New Modality DIS 1)

November 9 (Wed.) 9:00-11:30 Room A (3F 315)

Pharmacokinetic research to navigate the development of oligonucleotide therapeutics

• ChairsMakiya Nishikawa
  Faculty of Pharmaceutical Sciences, Tokyo University of Science
•  Masataka Oitate
  Group IV, Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.

• SY1-1Regulation and regulatory science on pharmacokinetics of oligonucleotide therapeutics
• SpeakerYoshiro Saito
  Division of Medicinal Safety Science, National Institute of Health Sciences
• SY1-2Pharmacokinetics assessment of oligonucleotides in Nippon Shinyaku
• SpeakerShunji Imai
  Pharmacokinetics and Safety Assessment Department, Discovery Research Laboratories, Nippon Shinyaku Co., Ltd.
• SY1-3DDS study on regulation of pharmacokinetics of nucleic acids
• SpeakerMakoto Oba
  Graduate School of Medical Science, Kyoto Prefectural University of Medicine
• SY1-4Study of supporting drug discovery and drug development of a new modality agent by 2-dimensional to 3-dimensional imaging pharmacokinetic analysis using high-intensity fluorescence-labeled probes
• SpeakerAkinobu Hamada
  Fundamental Innovative Oncology Core, National Cancer Center Research Institute

Symposium 2 (Drug Efficacy and Safety DIS)

November 9 (Wed.) 9:00-11:30 Room B (3F 313+314)

Utilisation of digital analytics technology for preventive and therapeutic medicine

• ChairsSatoru Koyanagi
  Kyushu University, Faculty of Pharmaceutical Sciences
•  Masanori Tachikawa
  Tokushima University, Institute of Biomedical Sciences

• SY2-1Data-driven drug discovery and healthcare by AI
• SpeakerYoshihiro Yamanishi
  Department of Bioscience and Bioinformatics, Faculty of Computer Science and Systems Engineering, Kyushu Institute of Technology
• SY2-2Prediction model for anticancer drug sensitivity using machine learning
• SpeakerMasashi Honma
  Department of Pharmacy, The University of Tokyo Hospital
• SY2-3Development of preventive methods to treat anticancer drug–induced adverse reactions using digital analysis technology on large-scale medical information databases
• SpeakerYoshito Zamami
  Department of Pharmacy, Okayama University Hospital
• SY2-4Personalized health management system by chronobiology and chrono-nutrition
• SpeakerYu Tahara
  Graduate School of Biomedical and Health Sciences, Hiroshima University

Symposium 3 (Drug Metabolism and Drug Induced Toxicity DIS 1)

November 9 (Wed.) 9:00-11:30 Room C (3F 311+312)

Recent Progress in Detection Methods and Toxicity Assessment of Reactive Metabolites of Carboxyl Group-containing Drugs

• ChairsKouichi Yoshinari
  Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka
•  Takahito Nishiyama
  Department of Drug Metabolism and Molecular Toxicology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

• SY3-1Characterization of enzymes determining the formations of acyl-glucuronidation and acyl-CoA conjugates
• SpeakerTatsuki Fukami
  Faculty of Pharmaceutical Sciences, Kanazawa University
• SY3-2Detection of acyl glucuronide-peptide adducts using dansylated Lys-Phe and its application to toxicity evaluation
• SpeakerAtsushi Iwamura
  DMPK Research Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation
• SY3-3Toxicity of acyl glucuronides and risk assessment - cysteine adduct detection
• SpeakerHiroshi Harada
  Drug Metabolism and Pharmacokinetics Research Lab., Kissei Pharmaceutical Co., LTD.
• SY3-4Bioactivation of diclofenac mediated by P450/UGT and the possible target proteins identified in human hepatocytes
• SpeakerKazuko Inoue
  Eisai Deep Human Biology Learning Medicine Development Biopharmaceutical Assessment Function Unit Global DMPK
• SY3-5Investigation of the trapping assay for reactive acyl CoA metabolites and their risk assessment
• SpeakerNobuyuki Kakutani
  Drug Metabolism & Pharmacokinetics Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc.

Symposium 4 (Modeling & Systems Pharmacology DIS)

November 9 (Wed.) 9:00-11:30 Room D (4F 411+412)

Compass for the future of Physiologically Based Pharmacokinetic Modelling

• ChairsMasayo Oishi
  Systems Pharmacology, Non-Clinical Biomedical Science, Applied Research & Operations, Astellas Pharma Inc.
•  Ryoko Sawamura
  Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd.
• SY4-1Developing a robust QSP model of AAV based gene therapy for clinical applications
• SpeakerNessy Tania
  Quantitative Systems Pharmacology, Early Clinical Development, Pfizer Worldwide Research, Development and Medical

• ChairsTakayo Ueno
  Bristol Myers Squibb
•  Yasuhisa Nagasaka
  Non-Clinical Biomedical Science, Applied Research & Operations, Astellas Pharma Inc.
• SY4-2Application of Physiologically Based Pharmacokinetic (PBPK) Modeling towards Discovery and Development of Cellular Therapies
• SpeakerAman P. Singh
  Clinical Pharmacology and Modeling, Oncology Cell Therapy and Therapeutic Area Unit, Takeda Development Center Americas, Cambridge MA

• ChairsYuki Iwaki
  Janssen Pharmaceutical Companies of Johnson & Johnson
•  Koji Chiba
  Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy
• SY4-3Mechanistic Considerations for Clinical-Translational GalNAc-siRNA Development: Insights from Minimal Physiologically-based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Modeling
• SpeakerVivaswath S. Ayyar
  Clinical Pharmacology & Pharmacometrics, Janssen Research & Development, LLC, USA

• ChairsTsuyoshi Minematsu
  Immuno-Oncology, Astellas Pharma Inc.
•  Shinichi Kijima
  Office of New Drug V/ Office of New Drug IV, Pharmaceuticals and Medical Devices Agency
• SY4-4Physiologically-Based Pharmacokinetic Modelling for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
• SpeakerHannah M Jones
  Certara UK Limited, Simcyp Division, Level 2-Acero

• ChairsRyosei Kawai
  Chuo Translational Science LLC
•  Teruki Hamada
  Discovery DMPK and Toxicology, Integrated & Translational Science, Axcelead Drug Discovery Partners, Inc.
• SY4-5Challenge of exploratory use of physiologically based pharmacokinetic model
• SpeakerKoji Chiba
  Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy

Symposium 5 (Absorption DIS)

November 9 (Wed.) 9:00-11:30 Room G (4F 419)

DRUG ABSORPTION FROM ZERO: The Deep Truth of Oral Drug Absorption Viewed from the Perspective of API/Drug Product
-From the Basics to the State-of-the-Art for Precision Drug Development-

• ChairsYoshiyuki Shirasaka
  Faculty of Pharmacy, Kanazawa University
•  Naomi Wakayama
  Eisai Co., Ltd.

• SY5-1Pharmacokinetic Perspective: Quantitative analysis of the impact of special formulation on nonlinear gastrointestinal absorption
• SpeakerYoshiyuki Shirasaka
  Faculty of Pharmacy, Kanazawa University
• SY5-2Pharmaceutical Perspective: considering the drug concentration in the GI　tract
• SpeakerShinji Yamashita
  Faculty of Pharmaceutical Sciences, Setsunan University
• SY5-3Formulation Perspective: Bioperformance assessment and Bioequivalence assurance
• SpeakerYasuhiro Tsume
  MSD
• SY5-4Regulatory perspectives: Permeability assessment in Biopharmaceutics Classification System-based biowaivers
• SpeakerHideaki Kuribayashi
  Office of New Drug I, Pharmaceuticals and Medical Devices Agency (PMDA)

Symposium 6 (Microphysiological system and iPS DIS)

November 10 (Thu.) 9:00-11:30 Room A (3F 315)

How should the cellular and organ models for MPS functionality be?

• ChairsSeiichi Ishida
  Sojo University
•  Hiroyuki Mizuguchi
  Graduate School of Pharmaceutical Sciences, Osaka University

• SY6-1Ideal cell and organ models from Pharma’s views- Case of AMED-MPS PJ-
• SpeakerHitoshi Naraoka
  Applied Research & Operations, Astellas Pharma Inc.
• SY6-2Case report of device evaluation tests by pharmaceutical companies in AMED-MPS
• SpeakerHiroyuki Moriguchi
  Non-Clinical Biomedical Science, Astellas Pharma Inc.
• SY6-3Development of human placenta models
• SpeakerHirokazu Kaji
  Tokyo Medical and Dental University
• SY6-4Human induced pluripotent stem cell-derived blood–brain barrier model for microphysiological system
• SpeakerYoshiharu Deguchi
  Faculty of Pharma-Sciences, Teikyo University
• SY6-5iPS cell-derived intestinal cells for evaluation of the intestinal absorption and safety of drugs
• SpeakerTakahiro Iwao
  Graduate School of Pharmaceutical Sciences, Nagoya City University
• SY6-6Development of liver-on-a-chips for pharmacokinetic and toxicity testing
• SpeakerKazuo Takayama
  Center for iPS Cell Research and Application, Kyoto University

Symposium 7 (BioAnalysis and BioImaging DIS)

November 10 (Thu.) 9:00-11:30 Room B (3F 313+314)

Biotransformation of Therapeutic Antibodies and Application to Drug Discovery

• ChairsMasamitsu Maekawa
  Graduate School of Pharmaceutical Sciences, Tohoku University
•  Junji Komaba
  Ono Pharmaceutical Co., Ltd

• SY7-1Biotransformation of therapeutic antibodies in the body
• SpeakerAtsushi Yonezawa
  Graduate School of Pharmaceutical Sciences, Kyoto University
• SY7-2Biotransformation evaluation of therapeutic monoclonal antibody using LC- MS
• SpeakerKazuhiro Kobayashi
  Pharmacokinetics Research Laboratories, Translational Research Unit, R&D Division, Kyowa Kirin Co. Ltd.
• SY7-3Bioanalytical approaches to evaluate in vivo behavior of ADCs
• SpeakerHideo Takakusa
  Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi-Sankyo Co., Ltd
• SY7-4Immunogenicity evaluation system using LC/MS (MAPPs) for therapeutic antibodies
• SpeakerNobuo Sekiguchi
  Discovery Biologics Dept., Chugai Pharmaceutical Co., Ltd.

Symposium 8 (New modality DIS 2)

November 10 (Thu.) 9:00-11:30 Room C (3F 311+312)

Up-to-date pharmacokinetic studies for gene therapy products

• ChairsTakashi Kuwabara
  Laboratory of Biologics evaluation,Yokohama University of Pharmacy
•  Yoichi Naritomi
  Healios K.K.

• SY8-1Biodistribution, PK/PD and Related Analytical Considerations for AAV Gene Therapy
• SpeakerShigeru Takeshita
  Clinical Pharmacology & Exploratory Development – Oncology, Astellas Pharma Inc.
• SY8-2Clinical pharmacology evaluation of Zolgensma
• SpeakerOkishi Mashita
  PK Sciences Japan, Translational Medicine, Novartis Pharma K.K.
• SY8-3Development of a replication-incompetent adenovirus vector and oncolytic adenovirus containing microRNA-mediated post-transcriptional de-targeting system
• SpeakerFuminori Sakurai
  Graduate School of Pharmaceutical Sciences, Osaka University
• SY8-4Evaluation methods of biodistribution and safety of gene therapy products
• SpeakerMasafumi Onodera
  Gene & Cell Therapy Promotion Center, National Center for Child Health and Development

Symposium 9 (Drug Metabolism and Drug Induced Toxicity DIS 2)

November 10 (Thu.) 9:00-11:30 Room F (4F 418)

Integrated understanding of functions of drug metabolism in the brain

• ChairsSeigo Sanoh
  School of Pharmaceutical Sciences, Wakayama Medical University
•  Tetsuya Nakagawa
  Preclinical Research Unit, Sumitomo Pharma Co., Ltd.

• SY9-1Cytochrome P450 enzymes in the brain
• SpeakerToshiro Niwa
  School of Pharmacy, Shujitsu University
• SY9-2Role of bioactive lipids produced by drug-metabolizing enzymes in the brain
• SpeakerAmi Oguro
  Graduate School of Biomedical and Health Sciences, Hiroshima University
• SY9-3Synthetic cannabinoids elicit elevation of endogenous cannabinoids: mechanism and the effect on learning and memory
• SpeakerYuji Ishii
  Graduate School of Pharmaceutical Sciences, Kyushu University
• SY9-4Potential of the Imaging Mass Spectrometry to understand the metabolism and distribution in brain
• SpeakerKenichi Watanabe
  Preclinical Research Unit, Sumitomo Pharma Co., Ltd.
• SY9-5Drug discovery research for anti-Parkinson's agents based on oxicam anti-inflammatory drugs
• SpeakerTomoyuki Ohe
  Faculty of Pharmacy, Keio University

Symposium 10 (Transporter DIS)

November 10 (Thu.) 9:00-11:30 Room G (4F 419)

Future perspectives in transporter-driven drug development

• ChairsKatsuhisa Inoue
  Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
•  Naoki Ishiguro
  Pharmacokinetic and Non-Clinical Safety, Nippon Boehringer Ingelheim Co., Ltd.

• SY10-1Novel approach for cancer therapy by simultaneous targeting of xCT-dependent cystine transport and aldehyde dehydrogenase activity
• SpeakerOsamu Nagano
  School of Medicine Institute for Advanced Medical Research (Division of Gene Regulation), Keio University
• SY10-2High-throughput screening technology for drug discovery research of membrane proteins and its applications ~transporters, claudins, etc.~
• SpeakerTakashi Motoyaji
  SEEDSUPPLY INC.
• SY10-3Receptor-mediated transport for delivery of macro- and middle-molecular drug across biological barriers
• SpeakerSumio Ohtsuki
  Faculty of Life Sciences, Kumamoto University
• SY10-4Activation of regulatory T cells through lactate transporter in the tumor environment
• SpeakerSyohei Koyama
  Division of Cancer Immunology, Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center

Symposium 11 (DDS DIS)

November 10 (Thu.) 13:00-15:30 Room C (3F 311+312)

DDS technologies in therapeutic peptides and nucleic acids-development -Introduction of AMED project for DDS-

• ChairsTatsuhiro Ishida
  Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University
•  Shigeru Kawakami
  Graduate School of Biomedical Sciences, Nagasaki University

• SY11-1Design of charge-reversible lipid nanoparticles for nucleic acid delivery
• SpeakerTomohiro Asai
  Department of Medical Biochemistry, University of Shizuoka School of Pharmaceutical Sciences
• SY11-2Controlling immune system by lipid nanoparticle
• SpeakerTakashi Nakamura
  Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University
• SY11-3Study of polymeric micelles for delivery of nucleic acid, peptide, protein therapeutics
• SpeakerNobuhiro Nishiyama
  Institute of Innovative Research, Tokyo Institute of Technology
• SY11-4Non-invasive transdermal drug delivery system using S/O technology as an alternative to injection
• SpeakerMasahiro Goto
  Transdermal Drug Delivery Research Center, Graduate School of Engineering, Kyushu University
• SY11-5Polypeptide encapsulation and in vivo transportation analysis of hyaluronic acid nanogel and its vaccine application
• SpeakerToru Katsumata
  New Product Development Office, Functional Additives Division, Asahi Kasei Corporation
• SY11-6Ionic liquid-based transcutaneous delivery of macromolecules
• SpeakerTaro Shimizu
  Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University

Symposium 12 (Regulation DIS)

November 10 (Thu.) 13:00-15:30 Room D (4F 411+412)

Drug-Drug Interactions: Latest trends on pharmacokinetic research including new modality and regulatory harmonization

• ChairsNaomi Nagai
  Research Institute of Pharmaceutical Sciences, Musashino University
•  Akihiro Ishiguro
  Office of Review Management, Pharmaceuticals and Medical Devices Agency

• SY12-1Summary and future plans of ICH M12（Drug Interaction Studies）draft guideline
• SpeakerMotohiro Hoshino
  Office of New Drug V, Pharmaceuticals and Medical Devices Agency
• SY12-2Discussion Points in ICH M12 (Drug Interaction Studies) draft guideline for implementation in Drug Research and Development
• SpeakerSo Miyoshi
  Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association/ Clinical Pharmacology, Pfizer R&D Japan
• SY12-3Current Status of Nonclinical Drug Interaction Studies on Oligonucleotide Drug Candidates: Results of a Questionnaire Survey of Pharmaceutical Companies
• SpeakerKei Fukuhara
  Task Force for DMPK Evaluation of Oligonucleotide Therapeutics, Japan Pharmaceutical Manufacturers Association/ Clinical Pharmacology, Pfizer R&D Japan
• SY12-4Current Research Trends in Quantitative Prediction of Drug Interactions
• SpeakerKazuya Maeda
  Kitasato University School of Pharmacy

Symposium 13 (Educational and Crosscutting DIS)

November 10 (Thu.) 13:00-15:30 Room G (4F 419)

Basic course of pharmacokinetics on cross-disciplinary

• ChairsTamihide Matsunaga
  Graduate School of Pharmaceutical Sciences, Nagoya City University
•  Takafumi Komori
  Biopharmaceutical Assessment Core Function Unit / Global DMPK, Eisai Co., Ltd.

• SY13-1The contribution of non-cytochrome P450 enzymes to drug metabolism and in vitro/in vivo evaluation in drug development: contribution of aldehyde oxidase to drug metabolism
• SpeakerSeigo Sanoh
  Laboratory of Pharmaceutical Health Science, School of Pharmaceutical Sciences, Wakayama Medical University
• SY13-2Reactive metabolite assessment in drug discovery research
• SpeakerMakoto Ozawa
  Discovery ADMET group, Pharmaceutical and biomedical research department, Daiichisankyo RD Novare Co.,Ltd.
• SY13-3In vitro assays for transporter-mediated DDIs: principles and theoretical considerations
• SpeakerYoshitane Nozaki
  Global DMPK, Eisai Co., Ltd.
• SY13-4Prediction of human pharmacokinetics of food-derived compounds based on in vitro tests
• SpeakerTakashi Kitaguchi
  Global Food Safety Institute, Nissin Foods Holdings Co., Ltd.

Asia Joint Symposium

November 9 (Wed.) 13:00-15:30 Room A (3F 315)

Brand-New Technologies to Open Up the Future of Drug Development

• ChairKazuya Maeda
  Kitasato University School of Pharmacy

• JSY-1CNS-targeted nanoDDS based on the nose-to-brain route
• SpeakerTakanori Kanazawa
  Department of Pharmaceutical Engineering & Drug Delivery Sciences, School of Pharmaceutical Sciences, University of Shizuoka
• JSY-2Pharmacometrics as a tool for optimization of dose regimens in malaria and cholangiocarcinoma
• SpeakerKesera Na-Bangchang
  Chulabhorn International College of Medicine and Drug Discovery and Development Center, Thammasat University
• JSY-3A novel integrated pharmacokinetic/pharmacodynamic model to assess combination therapy and application to anticancer drug synergism
• SpeakerYoung Hee Choi
  College of Pharmacy, Dongguk University
• JSY-4New therapeutic modality for liver diseases: from the metabolism regulation view
• SpeakerHuichang Bi
  School of Pharmaceutical Sciences, Southern Medical University

The Predoctoral Researcher-Initiative Session (PRIS) 2022

November 9 (Wed.) 14:30-17:00 Room D (4F 411+412)

Further Development of Drug Discovery Innovations by Mutual Improvement of Next Generation Researchers

• ChairsIori Azuma
  Laboratory of Molecular Pharmamacokinetics, Graduate School of Pharmaceutical Sciences, the University of Tokyo
•  Wangyang Liu
  Graduate School of Pharmacy, Takasaki University of Health & Welfare

• PSY-SLUtility of clinical pharmacokinetic information to establish reliable PBPK model parameters
• SpeakerKenta Yoshida
  Clinical Pharmacology, Genentech Research and Early Development
• PSY-1Drug delivery strategy via endocytic pathway exploiting lysosomal transporters
• SpeakerRyuto Tomabechi
  Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

• ChairsHiroki Sunakawa
  Graduate School of Pharmacy, Takasaki University of Health & Welfare
•  Yuta Tamemoto
  Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University
• PSY-2Nose-to-brain/spinal cord delivery kinetics of liposomes with different surface properties
• SpeakerTakayuki Oguma
  Graduate School of Pharmaceutical Sciences, University of Shizuoka
• PSY-3Characteristics of enzymes catalyzing oxidation of an alcohol group of small compounds
• SpeakerRei Sato
  Drug Metabolism and Toxicology, Graduate School of Pharmaceutical Sciences, Kanazawa University

• ChairsMiyuki Takemura
  Membrane Transport and Biopharmaceutics, Graduate School, Division of Pharmacy, Kanazawa University
•  Seiya Ohki
  Department of Clinical Pharmacy and Experimental Therapeutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
• PSY-4Evaluation of the risks of EGFR tyrosine kinase inhibitor-induced diarrhea with cultured intestinal stem cells originated from crypts in monkeys and humans
• SpeakerYoshiki Hashimoto
  Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo
• PSY-5Efficient adjuvant-free intranasal vaccine that harnesses previously induced antibodies as antigen-delivery carriers
• SpeakerAtsushi Kawai
  Laboratory of Nano-Design for Innovative Drug Development, Graduate School of Pharmaceutical Sciences, Osaka University

Chair's Session(Companies-Academia Young Exchange)

November 10 (Thu.) 9:00-11:30 Room E (4F 413)

Exchange event for young DMPK researchers in industry
<<Sailing to the Future from YOKOHAMA! >>

• OrganizerHiroshi Mizuuchi
  DMPK Research Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation
• OrganizerHideki Hirabayashi
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

Luncheon Seminar 1Sponsored by Miltenyi Biotec K.K.

November 8 (Tue.) 12:15-13:15 1F Main Hall

• ChairSohei Nakayama
  Department of marketing, Miltenyi Biotec K.K.

• LS1Microenvironmental Pharmacokinetic Evaluation Platform
  -from Organ to Organelle-
• SpeakerSyunsuke Yamamoto
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

Luncheon Seminar2Sponsored by Bio-Rad Laboratories, Inc.

November 8 (Tue.) 12:15-13:15 ROOM A (3F 315)

Advanced Application of Droplet Digital PCR in Pharmacokinetic Research
-Strategy and Assay Establishment for New Therapeutic Modality-

• ChairMasatoshi Soejima
  Life Science, Bio-Rad Laboratories, Inc.

• LS2-1Droplet Digital PCR Principle and Product Lineup
• SpeakerYukinori Yatsuda
  Life Science, Bio-Rad Laboratories K.K.
• LS2-2Pharmacokinetic research strategies using droplet digital PCR (ddPCR) analytical technology in the era of new therapeutic modalities
• SpeakerHideki Hirabayashi
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited
• LS2-3Establishment of a simple and versatile cell quantification method by droplet digital PCR using single surrogate calibration curve for various biological samples
• SpeakerMiyu Nakayama
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

Luncheon Seminar3Sponsored by AB Sciex Pte. Ltd.

November 8 (Tue.) 12:15-13:15 ROOM B (3F 313+314)

• LS3New technology : electronic activated dissociation leads to a new era of analysis - deep understanding of compounds
• SpeakerUshio Takeda
  SCIEX Market Development

Luncheon Seminar4Sponsored by CELLINK K.K./ MITSUWA FRONTECH Corp.

November 8 (Tue.) 12:15-13:15 ROOM C (3F 311+312)

3D In vitro Tissue Modeling: The Future of Medicine

• LS4-13D bioprinting technology for 3D human tissue models and vessel like micro-structure
• SpeakerRyo Asada
  CELLINK K.K.
• LS4-2New Developments in 3D Cellular Tissue
• SpeakerShoji Takeuchi
  Graduate School of Information Science and Technology, The University of Tokyo/ Kanagawa Institute of Industrial Science and Technology

Luncheon Seminar5Sponsored by PhoenixBio Co., Ltd.

November 9 (Wed.) 11:45-12:45 ROOM A (3F 315)

• ChairChise Tateno Mukaidani
  Research and Development Department and PXB- Mouse Production Department, PhoenixBio Co., Ltd.

• LS5-1Application of chimeric mice with humanized livers for predicting human pharmacokinetics of low-clearance compounds
• SpeakerKosuke Yoshida
  DMPK Research Laboratories, Sohyaku. Innovative Research Division, Mitsubishi Tanabe Pharma Corporation
• LS5-2Approach for predicting human metabolism of a mixed non-P450 and P450 substrate using chimeric mice with humanized liver (PXB-mice^®)
• SpeakerDaigo Asano
  Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.

Luncheon Seminar6Sponsored by Bruker Japan K.K.

November 9 (Wed.) 11:45-12:45 ROOM B (3F 313+314)

• LS6Highly Multiplexed Spatial Proteomics Using MALDI Imaging for Pharma and Immunohistology
• SpeakerMichael Easterling
  Bruker Corporation

Luncheon Seminar7Sponsored by Leica Microsystems K.K.

November 9 (Wed.) 11:45-12:45 ROOM C (3F 311+312)

Proof of concept for drug discovery and the latest developments in super-resolution imaging technology

• ChairShintaro Tanaka
  Leica Microsystems K.K.

• LS7-1Measurement of the intracellular dynamics of molecules with super-resolution, single-molecule microscope technologies
• SpeakerYasushi Okada
  Laboratory for Cell Polarity Regulation, Center for Biosystems Dynamics Research, RIKEN/ Department of Cell Biology, Department of Physics, UBI and WPI-IRCN, The University of Tokyo
• LS7-2Application and future perspective of super-resolution microscopy on intracellular distribution analysis
• SpeakersMiyu Nakayama, Akihiko Goto
  Takeda Pharmaceutical Company Limited
• LS7-3Trends in intracellular DDS research for biopharmaceuticals and examples of observations with the Leica STELLARIS super-resolution confocal microscope
• SpeakerToshiyuki Hatano
  Leica Microsystems K.K.

Luncheon Seminar8Sponsored by SEKISUI MEDICAL CO., LTD.

November 9 (Wed.) 11:45-12:45 ROOM D (4F 411+412)

Our efforts towards oligonucleotide drugs drug development and its pharmacokinetic evaluation

• ChairShinsuke Aoyama
  Drug Development Solutions Sales Office, SEKISUI MEDICAL CO., LTD.

• LS8-1Importance of chemical modifications and its effect in pharmacokinetics of antisense oligonucleotides
• SpeakerTadashi Umemoto
  Luxna Biotech Co., Ltd.
• LS8-2Sekisui Medical's approach for pharmacokinetic evaluation of oligonucleotide drugs
• SpeakerSatoshi Ito
  Contract Research Department, Drug Development Solutions Center, SEKISUI MEDICAL CO., LTD.

Luncheon Seminar9Sponsored by SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

November 9 (Wed.) 11:45-12:45 ROOM F (4F 418)

New Challenges Facing CROs Conducting Pharmacokinetic Studies

• ChairTakatoshi Nakamura
  Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd.

• LS9-1Learning from the Past - Classic but Novel 7-Ethoxycoumarin Metabolism -
• SpeakerKazuhide Iwasaki
  Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd.
• LS9-2New Modality - A Demanding Task -
• SpeakerUichiro Takagi
  Pharmacokinetics and Bioanalysis Center, Shin Nippon Biomedical Laboratories, Ltd.

Luncheon Seminar10Sponsored by KATAYAMA CHEMICAL INDUSTRIES Co., Ltd./
Tosoh Corporation/
GL Sciences, Inc./
Tecan Japan Co., Ltd.

November 9 (Wed.) 11:45-12:45 ROOM G (4F 419)

Latest analysis technology and drug delivery of oligonucleic acid

• ChairKensuke Shimizu
  Katayama chemical industries Co., Ltd.

• LS10-1Case study on oligo-nucleic acid analysis in pharmacokinetic research
• SpeakerHisashi Fujita
  Takeda Pharmaceutical Company Limited
• LS10-2Separation technique of oligo-nucleic acid by liquid chromatography
• SpeakerSeiji Ito
  Bioscience Division, Tosoh Corporation
• LS10-3Separation and Purification of Nucleic Acid Medicine Using Solid Phase Extraction
• SpeakerShigenori Ota
  Sales Planning Section, GL science Inc.
• LS10-4Solution for optimizing nucleic acid sample preparation
• SpeakerTatsumi Yoshihara
  Tecan Japan Co., Ltd.
• LS10-5Lipid nano particles(LNP)contract manufacturing service
• SpeakerHideki Minematsu
  Katayama chemical industries Co., Ltd.

Luncheon Seminar11Sponsored by Molecular Devices Japan, LLC/ MIMETAS Japan K.K.

November 10 (Thu.) 11:45-12:45 ROOM A (3F 315)

Next generation drug discovery pioneered by MPS

• ChairsTaro Nakazawa
  Product Solution, Molecular Devices Japan, LLC
•  Yoko Ejiri
  MIMETAS Japan K.K.

• LS11-1Organ on a Chip for Drug Discovery
• SpeakerYoko Ejiri
  MIMETAS Japan K.K.
• LS11-2Imaging solutions for quantification of assessment using MPS
• SpeakerTaro Nakazawa
  Product Solution, Molecular Devices Japan, LLC
• LS11-3Application of in vitro BBB model to drug discovery and development of CNS-targeting modality
• SpeakerShinji Iwasaki
  Drug Metabolism & Pharmacokinetics Research Laboratories, Research, Takeda Pharmaceutical Company Limited

Luncheon Seminar12Sponsored by KONICA MINOLTA, Inc.

November 10 (Thu.) 11:45-12:45 ROOM B (3F 313+314)

• ChairHiroyuki Kusuhara
  Graduate School of Pharmaceutical Sciences, the University of Tokyo

• LS12Pharmacokinetic and Pharmacodynamic analysis to predict clinical efficacy of anticancer agents in preclinical study
• SpeakerAkinobu Hamada
  Fundamental Innovative Oncology Core, National Cancer Center Research Institute

Luncheon Seminar13Sponsored by Becton Dickinson Japan

November 10 (Thu.) 11:45-12:45 ROOM C (3F 311+312)

• LS13Artificial adjuvant vector cells for treatment of cancer and infectious diseases
• SpeakerShin-ichiro Fujii
  Laboratory for Immunotherapy, RIKEN Center for Integrative Medical Science (IMS)/ Program for Drug Discovery and Medical Technology Platforms (DMP), RIKEN

Luncheon Seminar14Sponsored by Nihon Waters K.K.

November 10 (Thu.) 11:45-12:45 ROOM D (4F 411+412)

New Next Generation Solutions

• LS14-1Sensitive LC-MS/MS Bioanalytical Quantitation of Oligonucleotides
• SpeakerMotoji Oshikata
  Nihon Waters K.K.
• LS14-2High Mass Resolution and High Mass Accuracy MALDI/DESI MS Imaging
• SpeakerPaxton Thanai
  Nihon Waters K.K.

Luncheon Seminar15Sponsored by Pharmaron Japan LLC

November 10 (Thu.) 11:45-12:45 ROOM F (4F 418)

• ChairYoriko Tajima
  Pharmaron Japan LLC

• LS15Elucidation of idiosyncratic drug toxicity mechanism associated with HLA and potential application for prediction at preclinical stage
• SpeakerKousei Ito
  Graduate School of Pharmaceutical Sciences, Chiba University

Luncheon Seminar16Sponsored by Agilent Technologies Japan, Ltd.

November 10 (Thu.) 11:45-12:45 ROOM G (4F 419)

• ChairAkio Kori
  Pharmaceutical Business Development, Agilent Technologies Japan, Ltd.

• LS16Data Integrity and Digital Transformation in Pharmaceutical Analysis Laboratories -Improving Operational Efficiency and Data Reliability with Next-Generation LIMS/SDMS-
• SpeakerToshikazu Kobayashi
  Lab Informatics Group, Laboratory Solution Sales, Agilent Technologies Japan, Ltd.